Cell and Gene Outsourcing

  1. Accelerated LVV Manufacturing Enabled By Platform Excellence 11/25/2025

    Discover how a manufacturing platform enabled the rapid production of lentiviral vector in eight months. Learn the strategy used to balance speed, risk mitigation, and the highest quality standards.

  2. The Future of Biotech Outsourcing: Essential Skills for Program Managers 11/24/2025

    The next generation of program managers who liaise with contract manufacturers needs an expanded skillset to thrive.

  3. Custom Biospecimens Collections 11/17/2025

    With an in-house donor center and database of donors, along with an established network of hospitals and care centers, Precision can source virtually any disease type or sample type biospecimens needed for your project.

  4. How To Improve Sponsor–CMO Collaboration Around Digital Deviations 11/17/2025

    Digital strategies and standardized data models cut manual work, boost accuracy and speed of information sharing, and build trust between sponsors and CMOs.

  5. How One Biotech Company Is Accelerating The Drug Discovery Workflow 11/14/2025

    See how biotech innovation is accelerating drug discovery through AI, miniaturized workflows, and collaborative technologies to reshape how therapies are developed and delivered.

  6. Advanced Therapies Going Mainstream: Are We There Yet? 11/14/2025

    Advanced therapies are nearing mainstream adoption, with cell, mRNA, and oligonucleotide treatments expanding into broader indications. Learn what’s driving this shift and what manufacturers must do.

  7. Custom Media Development Services 11/14/2025

    Leverage custom media development services to optimize formulations for increased titers, quality, and manufacturability. Choose between traditional or multi-omics workflows to meet your cell line's specific needs.

  8. Biologically Expressed vs. Synthetic GLP-1 Peptides 11/14/2025

    Selecting the right GLP-1 peptide manufacturing route determines the specific impurity profile and regulatory strategy. Robust analytical methods are essential for ensuring efficacy and patient safety.

  9. Annex 1: Ensuring Sterile Pharmaceutical Manufacturing Standards 11/13/2025

    Adhering to the rigorous standards set by the EMA's Annex 1 requires strategic, risk-based compliance for facility design and processes, all of which is key to patient safety and future innovation.

  10. The Shift Toward Flexible FSP Models 11/13/2025

    Flexible FSP models are reshaping clinical outsourcing by offering sponsors scalable, cost-predictable partnerships that preserve control, enhance quality, and support long-term strategic goals.